ANI Pharmaceuticals’ (ANIP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $94.00 price target on the specialty pharmaceutical company’s stock.

Several other research firms have also commented on ANIP. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a “buy” rating and a $80.00 price objective for the company. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 14th. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price on the stock. Finally, Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $79.75.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $64.87 on Monday. The company has a market capitalization of $1.41 billion, a PE ratio of -117.95 and a beta of 0.63. The company has a 50-day simple moving average of $59.00 and a two-hundred day simple moving average of $58.12. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

Insider Activity at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares of the company’s stock, valued at $5,100,914.85. This represents a 0.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $191,776 in the last ninety days. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently made changes to their positions in ANIP. US Bancorp DE grew its position in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after purchasing an additional 531 shares during the period. KBC Group NV grew its position in ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in ANI Pharmaceuticals during the 4th quarter worth about $166,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares during the period. Finally, Rafferty Asset Management LLC acquired a new stake in ANI Pharmaceuticals during the 4th quarter worth about $200,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.